Patent intelligence · US
US 10231903
Pharmaceutical compounding methods and systems
Pharmaceutical compounding methods and systems
Patent details — US 10231903
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 19, 2019
- Expiration
- Mar 14, 2039
- Applicant
- MEDISCA PHARMACEUTIQUE INC.
- Claims
- 27
- CPC classes
- A61K, A61K31/045, A61K31/135, A61K31/137
Quick answer
US 10231903 (Pharmaceutical compounding methods and systems) is held by MEDISCA PHARMACEUTIQUE INC.. Status: granted. Granted Mar 19, 2019. Expires Mar 14, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- MEDISCA PHARMACEUTIQUE INC.
- Grant date
- Expiration
- Claims
- 27
- CPC classes
- A61K, A61K31/045, A61K31/135, A61K31/137, A61K31/192, A61K31/195
More from MEDISCA PHARMACEUTIQUE INC.
Related pharmaceutical patents in our USPTO index.
-
US 12427173
Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
granted -
US 12428415
Matriptase 2 inhibitors and uses thereof
granted -
US 12421236
Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor
granted -
US 12420085
Synergistic therapies for inter vertebral disc degeneration
granted -
US 12421231
Azaindole derivatives and their use as ERK kinase inhibitors
granted -
US 12403069
Adapter for use in a planetary mixer
granted -
US 12398179
Nanomolar peptides and derivatives to differentially modulate ephrin receptors
granted -
US 12396924
Adapter for use in a planetary mixer
granted
Frequently asked questions
What is US patent 10231903?
US 10231903 (Pharmaceutical compounding methods and systems) is held by MEDISCA PHARMACEUTIQUE INC.. Status: granted. Granted Mar 19, 2019. Expires Mar 14, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10231903?
MEDISCA PHARMACEUTIQUE INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 706 pharmaceutical patents for this assignee.
When does US 10231903 expire?
Our index shows an expiration date of Mar 14, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.